Genmab logo
Genmab
GMAB | NASDAQ
Chart Builder DCF Calculator
$51.57
+$0.20 (+0.39%)
At close: Nov 16, 2026, 4:00 PM ET
$51.75
+$0.18 (+0.35%)
After-hours: Nov 16, 2026, 7:30 PM ET

Genmab Company Profile

Company profile explained

Company Profile

Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.

Key Executives

Name Position
Jan van de Winkel Co-Founder, President & Chief Executive Officer
Anthony Pagano Executive Vice President & Chief Financial Officer
Christopher Cozic Executive Vice President & Chief People Officer
Gregory David Emil Mueller Executive VP, General Counsel & Chief Legal Officer
Judith V. Klimovsky Executive Vice President & Chief Development Officer
Martin Schultz Senior Director, Head of Development Business Partnership & Strategy and Director
Martine J. van Vugt Executive Vice President & Chief Strategy Officer
Mijke Zachariasse Vice President, Head of Antibody Research Materials & Director
Rayne Waller Executive Vice President & Chief Technical Operations Officer
Tahamtan Ahmadi Executive Vice President, Chief Medical Officer & Head of Experimental Medicines

Latest SEC Filings

Date Type Title
Oct 28, 2026 6-K Filing
Oct 23, 2026 6-K Filing
Oct 13, 2026 6-K Filing
Oct 07, 2026 6-K Filing
Oct 05, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Oct 05, 2026 6-K Filing
Oct 02, 2026 6-K Filing
Sep 29, 2026 6-K Filing
Sep 24, 2026 6-K Filing
Sep 09, 2026 6-K Filing
View All SEC Filings ➞
Genmab
Genmab logo
Country Denmark
IPO Date Jun 1, 2009
Industry Biotechnology
Sector Healthcare
Employees 3,119
CEO Jan van de Winkel

Contact Details

Carl Jacobsens Vej 30 Copenhagen, CD 2500 Denmark

Stock Details

Ticker Symbol GMAB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001434265
CUSIP Number 372303206
ISIN Number US3723032062
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.